Jun. 6 at 3:36 PM
$SPRY 1/2
Pharms SPRY — ARS PharmaceuticalsA Rare Convergence of Fundamentals + Short Squeeze
$ARS.X Pharmaceuticals (SPRY.US)$
The Product
ARS Pharmaceuticals makes neffy — the world’s first needle-free epinephrine nasal spray for severe allergic reactions (anaphylaxis). It’s FDA approved, European Commission approved, and Canada approved. The EpiPen market it’s disrupting is worth over
$1 billion annually. Millions of people with severe allergies avoid carrying EpiPens because of needle anxiety. neffy eliminates that barrier entirely.
The Short Squeeze Math
• 25.9 million shares sold short
• Only 200,000 shares available to borrow
• 61% of the entire float is short
• 22 days to cover at current volume
• Shorts need 129 days to exit at current borrow availability
• Borrow fees doubling week over week — currently 3.84%
• 74% of volume happening in dark pools to suppress price
• Shorts are mathematically trapped with no orderly exit
